Schiavone, Francesca http://orcid.org/0000-0002-8253-9581
,
Bathia, Riya http://orcid.org/0000-0002-1963-3831
Letchemanan, Krishna http://orcid.org/0000-0002-7886-4779
Masters, Lindsey http://orcid.org/0000-0002-1587-8065
Amos, Claire
Bara, Anna
Brown, Louise http://orcid.org/0000-0003-2827-6634
Gilson, Clare
Pugh, Cheryl
Atako, Nafisah
Hudson, Fleur
Parmar, Mahesh http://orcid.org/0000-0003-0166-1700
Langley, Ruth http://orcid.org/0000-0002-9706-016X
Kaplan, Richard S. http://orcid.org/0000-0002-0189-8348
Parker, Chris
Attard, Gert
Clarke, Noel W.
Gillessen, Silke
James, Nicholas D. http://orcid.org/0000-0002-7314-8204
Maughan, Tim
Sydes, Matthew R. http://orcid.org/0000-0002-9323-1371
Funding for this research was provided by:
Medical Research Council (171339, 171339 and 171339)
Efficacy and Mechanism Evaluation Programme (11/100/50)
Cancer Research UK (A13363 and 162082)
Novartis Pharmaceuticals UK Limited (158519)
Janssen Pharmaceuticals (163301)
Astellas Pharma US (163026)
AstraZeneca (158046)
Article History
Received: 10 August 2018
Accepted: 19 January 2019
First Online: 29 May 2019
Ethics approval and consent to participate
: The FOCUS4 and STAMPEDE trials have received favourable opinion by the relevant Research Ethics Committee (13/SC/0111 and 04/MRE07/35).
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.